Wockhardt’s inspection of its manufacturing unit at L-1, Chikalthana, Aurangabad by UK MHRA has been completed and there were no critical observations.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.